TScan Therapeutics, Inc. SEC filings TCRX
TScan Therapeutics, Inc. has 334 filings in SEC EDGAR's recent list, going back to Jul 26, 2019. Its latest annual report, Form ARS, was filed on Apr 17, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 12, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 16, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEF 14A | Proxy statement | Oct 26, 2026 | Nov 20, 2026 |
| PRE 14A | Preliminary proxy statement | Oct 16, 2026 | Nov 20, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 16, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 30, 2026 | Sep 24, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 11, 2026 | Sep 8, 2026 |
| 8-K |
Current report
Exit or restructuring costs, Listing notice, Officer or director change, Regulation FD disclosure, Other events
|
Sep 2, 2026 | Aug 27, 2026 |
| 8-K |
Current report
Agreement ended
|
Aug 18, 2026 | Aug 12, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Jun 22, 2026 | Jun 22, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Shareholder vote results
|
May 22, 2026 | May 20, 2026 |
| 10-Q | Quarterly report | May 6, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 6, 2026 | May 6, 2026 |
| ARS | Annual report to shareholders | Apr 17, 2026 | Dec 31, 2025 |
| DEF 14A | Proxy statement | Apr 17, 2026 | May 20, 2026 |
| PRE 14A | Preliminary proxy statement | Apr 7, 2026 | May 20, 2026 |
| 8-K |
Current report
Officer or director change
|
Apr 2, 2026 | Mar 31, 2026 |
| S-8 | Employee stock plan registration | Mar 4, 2026 | — |
| 10-K | Annual report | Mar 4, 2026 | Dec 31, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 4, 2026 | Mar 4, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jan 12, 2026 | Jan 12, 2026 |
| 8-K |
Current report
Officer or director change
|
Nov 26, 2025 | Nov 25, 2025 |
| 10-Q | Quarterly report | Nov 12, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2025 | Nov 12, 2025 |
| 8-K |
Current report
Exit or restructuring costs, Regulation FD disclosure, Other events
|
Nov 3, 2025 | Nov 3, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 9, 2025 | Sep 9, 2025 |
| 8-K |
Current report
Officer or director change
|
Aug 20, 2025 | Aug 14, 2025 |
| 10-Q | Quarterly report | Aug 12, 2025 | Jun 30, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2025 | Aug 12, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jul 2, 2025 | Jun 30, 2025 |
| ARS | Annual report to shareholders | May 14, 2025 | Dec 31, 2024 |
| DEFA14A | Additional proxy material | May 14, 2025 | — |
| DEF 14A | Proxy statement | May 14, 2025 | Jun 30, 2025 |
| 10-Q | Quarterly report | May 6, 2025 | Mar 31, 2025 |
| 8-K |
Current report
Results of operations
|
May 6, 2025 | May 6, 2025 |
| EFFECT | Filing | Mar 14, 2025 | — |
| CORRESP | Letter to the SEC | Mar 12, 2025 | — |
| UPLOAD | Letter from the SEC | Mar 11, 2025 | — |
| S-8 | Employee stock plan registration | Mar 5, 2025 | — |
| S-3 | Shelf registration | Mar 5, 2025 | — |
| 10-K | Annual report | Mar 5, 2025 | Dec 31, 2024 |
| 8-K |
Current report
Results of operations
|
Mar 5, 2025 | Mar 5, 2025 |
| 8-K |
Current report
Material agreement, Other events
|
Dec 26, 2024 | Dec 26, 2024 |
| 424B5 | Prospectus supplement | Dec 26, 2024 | — |
| 8-K |
Current report
Material agreement, Agreement ended, New debt, Regulation FD disclosure
|
Dec 23, 2024 | Dec 20, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 10, 2024 | Dec 9, 2024 |
| 8-K |
Current report
Unregistered share sale
|
Nov 21, 2024 | Nov 15, 2024 |
| 10-Q | Quarterly report | Nov 12, 2024 | Sep 30, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2024 | Nov 12, 2024 |
| 8-K |
Current report
Material agreement
|
Nov 1, 2024 | Oct 28, 2024 |
| 10-Q | Quarterly report | Aug 12, 2024 | Jun 30, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2024 | Aug 12, 2024 |
| S-8 | Employee stock plan registration | Jun 14, 2024 | — |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 14, 2024 | Jun 12, 2024 |
| 10-Q | Quarterly report | May 13, 2024 | Mar 31, 2024 |
| 8-K |
Current report
Results of operations
|
May 13, 2024 | May 13, 2024 |
| ARS | Annual report to shareholders | Apr 30, 2024 | Dec 31, 2023 |
| DEFA14A | Additional proxy material | Apr 30, 2024 | — |
| DEF 14A | Proxy statement | Apr 30, 2024 | Jun 12, 2024 |
| 424B5 | Prospectus supplement | Apr 18, 2024 | — |
| 8-K |
Current report
Material agreement, Results of operations, Other events
|
Apr 17, 2024 | Apr 16, 2024 |
| FWP | Free writing prospectus | Apr 17, 2024 | — |
| 424B5 | Prospectus supplement | Apr 16, 2024 | — |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Apr 16, 2024 | Apr 16, 2024 |
| EFFECT | Filing | Apr 12, 2024 | — |
| CORRESP | Letter to the SEC | Apr 10, 2024 | — |
| 10-K/A | Amended annual report | Apr 10, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Other events
|
Apr 8, 2024 | Apr 8, 2024 |
| UPLOAD | Letter from the SEC | Mar 7, 2024 | — |
| S-3 | Shelf registration | Mar 6, 2024 | — |
| S-8 | Employee stock plan registration | Mar 6, 2024 | — |
| 10-K | Annual report | Mar 6, 2024 | Dec 31, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 6, 2024 | Mar 6, 2024 |
| 8-K |
Current report
Officer or director change
|
Jan 29, 2024 | Jan 24, 2024 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 11, 2023 | Dec 9, 2023 |
| 8-K |
Current report
Officer or director change
|
Dec 7, 2023 | Dec 6, 2023 |
| 10-Q | Quarterly report | Nov 9, 2023 | Sep 30, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2023 | Nov 9, 2023 |
| 10-Q | Quarterly report | Aug 10, 2023 | Jun 30, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2023 | Aug 10, 2023 |
| 8-K |
Current report
Officer or director change
|
Jul 25, 2023 | Jul 20, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jun 29, 2023 | Jun 27, 2023 |
| S-8 | Employee stock plan registration | Jun 16, 2023 | — |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 16, 2023 | Jun 13, 2023 |
| DEFA14A | Additional proxy material | Jun 2, 2023 | — |
| 8-K |
Current report
Material agreement, Other events
|
May 31, 2023 | May 25, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
May 31, 2023 | May 24, 2023 |
| 424B5 | Prospectus supplement | May 30, 2023 | — |
| FWP | Free writing prospectus | May 26, 2023 | — |
| 424B5 | Prospectus supplement | May 25, 2023 | — |
| 8-K |
Current report
Other events
|
May 17, 2023 | May 17, 2023 |
| EFFECT | Filing | May 16, 2023 | — |
| EFFECT | Filing | May 16, 2023 | — |
| 8-K |
Current report
Other events
|
May 16, 2023 | May 16, 2023 |
| 424B5 | Prospectus supplement | May 16, 2023 | — |
| AW | Filing | May 16, 2023 | — |
| S-3/A | Filing | May 16, 2023 | — |
| S-3/A | Filing | May 16, 2023 | — |
| S-3/A | Filing | May 16, 2023 | — |
| CORRESP | Letter to the SEC | May 15, 2023 | — |
| CORRESP | Letter to the SEC | May 15, 2023 | — |
| CORRESP | Letter to the SEC | May 10, 2023 | — |
| CORRESP | Letter to the SEC | May 10, 2023 | — |
| 10-Q | Quarterly report | May 10, 2023 | Mar 31, 2023 |
| 8-K |
Current report
Results of operations
|
May 10, 2023 | May 10, 2023 |
| 8-K |
Current report
Material agreement, Regulation FD disclosure
|
May 9, 2023 | May 8, 2023 |
| ARS | Annual report to shareholders | Apr 25, 2023 | Dec 31, 2022 |
| DEFA14A | Additional proxy material | Apr 25, 2023 | — |
| DEF 14A | Proxy statement | Apr 25, 2023 | Jun 13, 2023 |
| 8-K |
Current report
Officer or director change
|
Apr 10, 2023 | Apr 6, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Mar 31, 2023 | Mar 27, 2023 |
| S-8 | Employee stock plan registration | Mar 8, 2023 | — |
| 10-K | Annual report | Mar 8, 2023 | Dec 31, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 8, 2023 | Mar 8, 2023 |
| 8-K |
Current report
Other events
|
Jan 23, 2023 | Jan 23, 2023 |
| UPLOAD | Letter from the SEC | Nov 15, 2022 | — |
| UPLOAD | Letter from the SEC | Nov 15, 2022 | — |
| S-3 | Shelf registration | Nov 9, 2022 | — |
| S-3 | Shelf registration | Nov 9, 2022 | — |
| 10-Q | Quarterly report | Nov 9, 2022 | Sep 30, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2022 | Nov 9, 2022 |
| 8-K |
Current report
Material agreement, New debt, Regulation FD disclosure
|
Sep 12, 2022 | Sep 12, 2022 |
| 10-Q | Quarterly report | Aug 10, 2022 | Jun 30, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 10, 2022 | Aug 10, 2022 |
| 8-K |
Current report
Officer or director change
|
Jul 7, 2022 | Jul 7, 2022 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 3, 2022 | Jun 1, 2022 |
| 8-K |
Current report
Other events
|
May 31, 2022 | May 31, 2022 |
| 10-Q | Quarterly report | May 12, 2022 | Mar 31, 2022 |
| 8-K |
Current report
Results of operations
|
May 9, 2022 | May 9, 2022 |
| DEFA14A | Additional proxy material | Apr 21, 2022 | — |
| DEF 14A | Proxy statement | Apr 21, 2022 | Jun 1, 2022 |
| S-8 | Employee stock plan registration | Mar 9, 2022 | — |
| 10-K | Annual report | Mar 9, 2022 | Dec 31, 2021 |
| 8-K |
Current report
Results of operations
|
Mar 9, 2022 | Mar 9, 2022 |
| 8-K |
Current report
Other events
|
Jan 24, 2022 | Jan 24, 2022 |
| 8-K |
Current report
Material agreement, New debt
|
Dec 2, 2021 | Dec 2, 2021 |
| 10-Q | Quarterly report | Nov 10, 2021 | Sep 30, 2021 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2021 | Nov 10, 2021 |
| 10-Q | Quarterly report | Aug 19, 2021 | Jun 30, 2021 |
| 8-K |
Current report
Results of operations
|
Aug 19, 2021 | Aug 19, 2021 |
| 8-K |
Current report
Officer or director change, Bylaw or fiscal year change
|
Jul 20, 2021 | Jul 15, 2021 |
| 424B4 | Prospectus | Jul 19, 2021 | — |
| S-8 | Employee stock plan registration | Jul 16, 2021 | — |
| FWP | Free writing prospectus | Jul 16, 2021 | — |
| EFFECT | Filing | Jul 15, 2021 | — |
| S-1MEF | Filing | Jul 15, 2021 | — |
| SEC STAFF LETTER | Filing | Jul 15, 2021 | — |
| CERT | Filing | Jul 15, 2021 | — |
| CORRESP | Letter to the SEC | Jul 14, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 13, 2021 | — |
| 8-A12B | Filing | Jul 13, 2021 | — |
| CORRESP | Letter to the SEC | Jul 13, 2021 | — |
| CORRESP | Letter to the SEC | Jul 13, 2021 | — |
| S-1/A | Amended registration statement | Jul 12, 2021 | — |
| S-1/A | Amended registration statement | May 14, 2021 | — |
| CORRESP | Letter to the SEC | May 5, 2021 | — |
| S-1/A | Amended registration statement | May 5, 2021 | — |
| UPLOAD | Letter from the SEC | May 3, 2021 | — |
| CORRESP | Letter to the SEC | Apr 30, 2021 | — |
| S-1/A | Amended registration statement | Apr 30, 2021 | — |
| CORRESP | Letter to the SEC | Apr 30, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 29, 2021 | — |
| SEC STAFF LETTER | Filing | Apr 28, 2021 | — |
| CORRESP | Letter to the SEC | Apr 23, 2021 | — |
| S-1 | Registration statement | Apr 23, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 15, 2021 | — |
| SEC STAFF LETTER | Filing | Apr 12, 2021 | — |
| DRS | Filing | Mar 19, 2021 | — |
| D | Filing | Jan 28, 2021 | — |
| D | Filing | Jul 26, 2019 | — |
Showing 170 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- TCRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1783328
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.